A decrease in circulating CRP levels in MSC-treated patients 1 month after the first infusion only in patients with elevated CRP levels at baseline suggests that MSCs might inhibit systemic inflammation in COPD. This evidence concerns the gene CRP and chronic obstructive pulmonary disease.